Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Scedosporiasis and recent advances in antifungal therapy

Transplant Infectious Disease

Volumn 4, Issue 4, 2002, Pages 212-217

  Safdar, Amar ^a,b,c   Papadopoulos, E B ^a,b   Young, J W ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Amphotericin B resistance; Breakthrough mycosis; New antifungals; Pseudallescheria boydii; Scedosporium apiospermum

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CEFTAZIDIME; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; METHOTREXATE; PREDNISONE; THYMOCYTE ANTIBODY; VORICONAZOLE;

ADULT; ARTICLE; AUTOPSY; BRAIN ABSCESS; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LUNG ASPERGILLOSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SCEDOSPORIUM APIOSPERMUM;

EID: 0036966314     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2002.02008.x     Document Type: Article

References (41)

1. TADROS TS, WORKOWSKI KA, SIEGEL RJ, HUNTER S, SCHWARTZ DA. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Human Pathol 1998: 29: 1266-1272.
2. BADDLEY JW, STROUD TP, SALZMAN D, PAPPAS PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001: 32: 1319-1324.
3. GARCIA-ARATA MI, OTERO MJ, ZOMENO M, DE LA FIGUERA MA, DE LAS CUEVAS MC, LOPEZ-BREA M. Scedosporium apiospermum pneumonia after autologous bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1996: 15: 600-603.
4. KUSNE S, ARIYANAYAGAM-BAKSH S, STROLLO DC, ABERNETHY J. Invasive Scedosporium apiospermum infection in a heart transplant recipient presenting with multiple skin nodules and a pulmonary consolidation. Transplant Infect Dis 2000: 2: 194-196.
5. HOFMAN P, SAINT-PAUL MC, GARI-TOUSSAINT M, et al. Disseminated infection due to Scedosporium apiospermum in liver transplantation. Differential diagnosis from invasive aspergillosis. Ann Pathol 1993: 13: 332-335.
6. BEN HAMIDA M, BEDROSSIAN J, PRUNA A, FOUQUERAY B, METIVIER F, IDATTE JM. Fungal mycotic aneurysms and visceral infection due to Scedosporium apiospermum in a kidney transplant patient. Transplant Proc 1993: 25: 2290-2291.
7. GROLL AH, WALSH TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001: 7 (Suppl. 2): 8-24.
8. CUENCA-ESTRELLA M, RUIZ-DIEZ B, MARTINEZ-SUAREZ JV, MONZON A, RODRIGUEZ-TUDELA JL. Comparative in-vitro activity of voriconazole (UK-109, 496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 1999: 43: 149-151.
9. JOHNSON EM, SZEKELY A, WARNOCK DW. In-vitro activity of voriconazole, itraconazole, and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998: 42: 741-745.
10. National Committe for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibilty testing of conidium forming filamentous fungi: proposed standard M38-P. Wayne, PA: NCCLS, 1998.
11. BODET CA 3RD, JORGENSEN JH, DRUTZ DJ. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol 1985: 22: 157-160.
12. CASTRO LG, BELDA W JR, SALEBIAN A, CUCE LC. Mycetoma: a retrospective study of 41 cases seen in Sao Paulo, Brazil, from 1978 to 1989. Mycoses 1993: 36: 89-95.
13. RUMELT S, COHEN I, LEFLER E, REHANY U. Corneal co-infection with Scedosporium apiospermum and Acanthamoeba after sewage-contaminated ocular injury. Cornea 2001: 20: 112-116.
14. KIRAZ N, GULBAS Z, AKGUN Y, UZUN O. Lymphadenitis caused by Scedosporium apiospermum in an immunocompetent patient. Clin Infect Dis 2001: 32: E59-E61.
15. CANET JJ, PAGEROLS X, SANCHEZ C, VIVES P, GARAU J. Lymphocutaneous syndrome due to Scedosporium apiospermum. Clin Microbiol Infect 2001: 7: 648-652.
16. SOBOTTKA I, DENEKE J, POTHMAN W, HEINEMANN A, MACK D. Fatal native valve endocarditis due to Scedosporium apiospermum (Pseudallescheria boydii) following trauma. Eur J Clin Microbiol Infect Dis 1999: 18: 387-389.
17. RUCHEL R, WILICHOWSKI E. Cerebral Pseudallescheria mycosis after near-drowning. Mycoses 1995: 38: 473-475.
18. SAFDAR A, ARMSTRONG D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin 2001: 17: 531-570.
19. MANUEL RJ, KIBBLER CC. The epidemiology and prevention of invasive aspergillosis. J Hospital Infect 1998: 39: 95-109.
20. SUMMERBELL RC, KRAJDEN S, KANE J. Potted plants in hospitals as reservoirs of pathogenic fungi. Mycopathologia 1989: 106: 13-22.
21. ITIN PH, FREI R, LAUTENSCHLAGER S, et al. Cutaneous manifestation of Paecilomyces lilacinus infection induced by a contaminated skin lotion in patients who are severely immunocompromised. J Am Acad Dermatol 1998: 39: 401-409.
22. SAFDAR A, BRYAN CS, GRAYBILL JR. Fungal infections and antifungal drug therapy. In: BRYAN CS, ed. Infectious Diseases in Primary Care. Philadelphia: W.B. Saunders, 2002: 493-514.
23. PATTERSON TF. Approaches to fungal diagnosis in transplantation. Transplant Infect Dis 1999: 1: 262-272.
24. FRATER JL, HALL GS, PROCOP GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Laboratory Med 2001: 125: 375-378.
25. SAFDAR A, DOMMERS MP, TALWANI R, THOMPSON CR. Intracranial perineural extension of invasive mycosis: a novel mechanism of disease propagation by Aspergillus fumigatus. Clin Infect Dis 2002: 35: E50-E53.
26. BEKERSKY I, BOSWELL GW, HILES R, FIELDING RM, BUELL D, WALSH TJ. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm Res 2000: 17: 1494-1502.
27. CLEMONS KV, SOBEL RA, WILLIAMS PL, PAPPAGIANIS D, STEVENS DA. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2002: 46: 2420-2426.
28. MACHARD S, THEODORO F, BENECH H, GROGNET JM, EZAN E. A sensitive amphotericin B immunoassay for pharmacokinetic and distribution studies. Antimicrob Agents Chemother 2000: 44: 546-550.
29. BOWMAN JC, HICKS PS, KURTZ MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002: 46: 3001-3012.
30. GRAYBILL JR, BURGESS DS, HARDIN TC. Key issues concerning fungistatic versus fungicidal drugs. Eur J Clin Microbiol Infect Dis 1997: 16: 42-50.
31. PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN, DIEKEMA DJ. In vitro activity of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002: 46: 1723-1727.
32. PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN. SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002: 46: 1032-1037.
33. HERBRECHT R, DENNING DW, PATTERSON TF, et al. Voriconaozle versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002: 347: 408-415.
34. MELETIADIS J, MEIS JF, MOUTON JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002: 46: 62-68.
35. ESPINEL-INGROFF A. In vitro fungicidal activity of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dermatiaceous fungi. J Clin Microbiol 2001: 39: 954-958.
36. GIL-LAMAIGNERE C, ROILIDES E, MOSQUERA J, MALOUKOU A, WALSH TJ. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002: 46: 2234-2237.
37. NESKY MA, MCDOUGAL EC, PEACOCK JE JR. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000: 31: 673-677.
38. PFALLER MA, MARCO F, MESSER SA, JONES RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998: 30: 251-255.
39. DENNING DW. Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Antimicrobial Chemother 1997: 40: 611-614.
40. GROLL AH, MICKIENE D, PETRAITIS V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK-463) in rabbits. Antimicrob Agents Chemother 2001: 45: 3322-3327.
41. SABLE CA, NGUYEN BY, CHODAKEWITZ JA, DINUBILE MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infect Dis 2002: 4: 25-30.